
Opinion|Videos|October 15, 2024
Exploring Oral Systemic Therapies For Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations
Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.
Advertisement
Advertisement
Related to this article

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.

Suceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome
4
Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial
5


